Read More
Hutchmed (China) (0013) said it has initiated the phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
The first patient received the first dose in China on Thursday, the company said.
This first-in-class antibody-targeted therapy conjugate (ATTC) drug candidate comprises a highly selective and potent Kirsten rat sarcoma (KRAS) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody, it said.
An ATTC enables tumor-specific activity of potent, cell-killing, targeted therapy payloads by leveraging antibody-guided delivery. Colorectal, pancreatic and lung cancers have the highest incidence of patients with KRAS-altered tumors, who often lack a safe and durable KRAS therapy.
HMPL-A830 is designed to address this need by delivering a KRAS inhibitor directly to
EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability, Hutchmed said.
This first-in-human, multicenter, open-label Phase I clinical study evaluates the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HMPL-A830, it noted.
The current study consists of a Phase Ia dose escalation part to determine the maximum tolerated dose and recommended dose for expansion, the drugmaker said, adding that the subsequent dose expansion/optimization part is to further characterize its safety, tolerability and preliminary anti-tumor activity in selected solid tumors.














